CSL's Financial Results
CSL's Half Year financial results were announced on Wednesday, 12th February 2020. Please click the link below to view our historic Full Year and Half Year Financial Results.More Information
Search Results123 results found
We have announced our 2019 Half Year Results.
CSL Limited have announced 2018 Full Year Results for the period ending 30 June 2018. Full details available here.
CSL's exceptionally strong performance is a result of the focused execution of our strategy. Learn more.
The myelin sheath, or the protective covering of the nerves, is damaged, which In October 2018, an expanded age indication for AFLURIA® may result in numbness or tingling, muscle weakness, fatigue QUADRIVALENT (influenza vaccine) for use in people six and other symptoms which worsen over time.
AASB 16 - Leases There are no matters or circumstances which have arisen since 31 December This standard introduces a single lessee accounting model and requires a lessee 2018 which have significantly affected, or may significantly affect, the to recognise assets and liabilities for all leases with a term of more than 12 operations of the Group, the results of operations, or the state of affairs of months, unless the underlying asset is of low value.
Translational Medicine was opened in December 2018.
pending test results after 2018), CSL Plasma donors related their Find out more at Find out more at a donation is made.*
You should read these Risk Factors along with our Annual Report for the fiscal year ending 30 June 2018 and the announcement of the Financial Results to 30 June 2018, available as described under "General Information— Documents Available for Inspection", which provide a more complete description of our business and any public announcements.
GROUP RESULTS Dec Dec Dec Half year ended December 2017 2018 2018 Change US$ Millions REPORTED REPORTED AT CC1 % Sales 3,999 4,343 4,417 11 Other Revenue / Income 148 162 164 Total Revenue / Income 4,147 4,505 4,581 11 Earnings before Interest, Tax, Depreciation & Amortisation 1,617 1,719 1,734 7 Depreciation/Amortisation (141) (166) (168) Earnings before Interest and Tax 1,476 1,553 1,566 6 Net Interest Expense (52) (93) (58) Tax Expense (338) (300) (311) Net Profit after Tax 1,086 1,161 1,196 10
the conduct of Board and committee CSL is committed to ensuring that it has 2018 the Nomination Committee will Governance and Nomination Committee meetings, including the effectiveness competitive remuneration and human adopt a new charter and be renamed the suggested a number of actions for of discussion and debate at those resources policies and practices that Corporate Governance and Nomination improvement as a result of this review.